CA2689664A1 - Cancer treatment combination therapy comprising vinflunine and trastuzumab - Google Patents

Cancer treatment combination therapy comprising vinflunine and trastuzumab Download PDF

Info

Publication number
CA2689664A1
CA2689664A1 CA2689664A CA2689664A CA2689664A1 CA 2689664 A1 CA2689664 A1 CA 2689664A1 CA 2689664 A CA2689664 A CA 2689664A CA 2689664 A CA2689664 A CA 2689664A CA 2689664 A1 CA2689664 A1 CA 2689664A1
Authority
CA
Canada
Prior art keywords
vinflunine
trastuzumab
cancer
weeks
neoplasm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2689664A
Other languages
English (en)
French (fr)
Inventor
Bart Vanhauwere
Marie-Claire Pinel
Francois-Michel Delgado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Pierre Fabre Medicament SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38353425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2689664(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2689664A1 publication Critical patent/CA2689664A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2689664A 2007-05-31 2008-05-29 Cancer treatment combination therapy comprising vinflunine and trastuzumab Abandoned CA2689664A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290679.5 2007-05-31
EP07290679A EP1997534A1 (en) 2007-05-31 2007-05-31 Cancer treatment combination therapy comprising vinflunine and trastuzumab
PCT/EP2008/056620 WO2008145697A1 (en) 2007-05-31 2008-05-29 Cancer treatment combination therapy comprising vinflunine and trastuzumab

Publications (1)

Publication Number Publication Date
CA2689664A1 true CA2689664A1 (en) 2008-12-04

Family

ID=38353425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2689664A Abandoned CA2689664A1 (en) 2007-05-31 2008-05-29 Cancer treatment combination therapy comprising vinflunine and trastuzumab

Country Status (18)

Country Link
US (1) US20100196363A1 (enExample)
EP (2) EP1997534A1 (enExample)
JP (1) JP2010528091A (enExample)
KR (1) KR20100017752A (enExample)
CN (1) CN101687104A (enExample)
AR (1) AR066778A1 (enExample)
AU (1) AU2008257555A1 (enExample)
BR (1) BRPI0812280A2 (enExample)
CA (1) CA2689664A1 (enExample)
CL (1) CL2008001589A1 (enExample)
IL (1) IL202393A0 (enExample)
MX (1) MX2009012874A (enExample)
NO (1) NO20093536L (enExample)
RU (1) RU2009146882A (enExample)
TN (1) TN2009000490A1 (enExample)
TW (1) TW200908976A (enExample)
WO (1) WO2008145697A1 (enExample)
ZA (1) ZA200908247B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
PL4234033T3 (pl) 2011-10-14 2025-04-28 F. Hoffmann-La Roche Ag Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2
EP3800204A1 (en) 2013-04-16 2021-04-07 F. Hoffmann-La Roche AG Pertuzumab variants and evaluation thereof
EP3481422A1 (en) * 2016-07-06 2019-05-15 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
CR20190376A (es) 2017-01-17 2019-11-20 Genentech Inc Formulaciones de anticuerpos de her2 subcutáneas
KR20190096384A (ko) 2017-03-02 2019-08-19 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
NO20093536L (no) 2009-12-16
WO2008145697A1 (en) 2008-12-04
IL202393A0 (en) 2010-06-30
AR066778A1 (es) 2009-09-09
MX2009012874A (es) 2010-03-31
EP2164573A1 (en) 2010-03-24
TW200908976A (en) 2009-03-01
AU2008257555A1 (en) 2008-12-04
KR20100017752A (ko) 2010-02-16
ZA200908247B (en) 2010-10-27
US20100196363A1 (en) 2010-08-05
TN2009000490A1 (en) 2011-03-31
EP1997534A1 (en) 2008-12-03
CN101687104A (zh) 2010-03-31
BRPI0812280A2 (pt) 2014-11-18
CL2008001589A1 (es) 2009-03-06
RU2009146882A (ru) 2011-07-10
JP2010528091A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
US20100196363A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
KR102446673B1 (ko) 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도
AU2016309002A1 (en) Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment
EP3042669B1 (en) Antitumor agent and antitumor effect enhancer
JP2018506550A (ja) 癌治療のための併用療法
CA3215047A1 (en) Therapeutic compositions and methods for treating tumors
TW201311274A (zh) 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法
Akinleye et al. Novel agents for advanced pancreatic cancer
KR20240130081A (ko) 항-trop-2 항체-약물 접합체와 추가 치료제의 병용 사용
Kim et al. A single-arm, prospective, phase II study of cisplatin plus weekly docetaxel as first-line therapy in patients with metastatic or recurrent salivary gland cancer
US20230201303A1 (en) Methods for treating pancreatic cancer and other solid tumors
US20120196828A1 (en) Sensitization of cancer cells to treatment
Smith et al. Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer
Tanaka et al. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience
WO2023079177A1 (en) Lurbinectedin and atezolizumab combinations
KR20250133269A (ko) 나노입자 및 방사성 의약품을 사용한 조합 요법
HK1139345A (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
EP4659741A1 (en) Use of paclitaxel cationic liposome in treating tumors
Dragnev et al. A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors
Patnaik et al. ENZ-2208, a novel anticancer agent, in patients with advanced malignancies: a phase 1 dose-escalation study
TW202527951A (zh) 用於治療乳腺癌的方法
CN107126563B (zh) 含低剂量阻断vegf信号通路的抗体的组合物及其用途
Kelly et al. 404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors
Modi et al. 7 Development of Inhibitors
HK1257249B (en) Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130529